<DOC>
	<DOCNO>NCT00002615</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . Combining one drug may kill tumor cell . It know whether receive chemotherapy surgery may effective surgery alone treat patient stomach cancer . PURPOSE : Randomized phase III trial compare effectiveness surgery plus combination chemotherapy surgery alone treat patient stomach cancer .</brief_summary>
	<brief_title>Surgery With Without Combination Chemotherapy Treating Patients With Stomach Cancer</brief_title>
	<detailed_description>OBJECTIVES : - Compare survival quality life patient resectable stage II III adenocarcinoma stomach treat epirubicin , cisplatin , fluorouracil resection v resection alone . - Determine effect perioperative chemotherapy resectability gastric cancer patient . OUTLINE : This randomize , multicenter study . Patients stratify center performance status ( 0 vs 1 ) . - Arm I : Patients undergo radical total gastrectomy radical subtotal distal gastrectomy , discretion surgeon , perigastric lymph node dissection . Patients also may undergo lymphadenectomy discretion surgeon . At begin laparotomy , pre-aortic , infra-colic node sample staging purpose frozen section examine surgery . Patients find metastatic disease undergo palliative resection discretion surgeon postoperative chemotherapy discretion oncologist . - Arm II : Patients receive fluorouracil ( 5-FU ) IV continuously 3 week cisplatin IV 4 hour ( begin 4 hour initiation 5-FU infusion ) epirubicin IV day 1 ( ECF ) . Treatment continue every 3 week 3 course . Within 6 week completion course 3 blood count recover , patient undergo resection arm I . Beginning within 4-6 week surgery , patient receive 3 additional course ECF . Quality life assess baseline , completion study therapy , every 6 month 2 year . Patients follow every 6 month 2 year annually thereafter . PROJECTED ACCRUAL : A total 500 patient accrue study within 4 year .</detailed_description>
	<mesh_term>Stomach Neoplasms</mesh_term>
	<mesh_term>Fluorouracil</mesh_term>
	<mesh_term>Epirubicin</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically proven resectable stage II III adenocarcinoma stomach No evidence locally inoperable distant metastasis chest xray combination abdominal ultrasound , CT scan , laparoscopy PATIENT CHARACTERISTICS : Age : Any age Performance status : WHO 01 Hematopoietic : Not specify Hepatic : Not specify Renal : Creatinine clearance great 60 mL/min Cardiovascular : No clinical evidence uncontrolled angina pectoris , cardiac failure , significant uncontrolled cardiac arrhythmia Other : No medical contraindication study therapy No prior malignancy except nonmelanomatous skin cancer carcinoma situ cervix Not pregnant PRIOR CONCURRENT THERAPY : Biologic therapy : Not specify Chemotherapy : No prior chemotherapy Endocrine therapy : Not specify Radiotherapy : No prior radiotherapy Surgery : See Disease Characteristics</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2001</verification_date>
	<keyword>stage II gastric cancer</keyword>
	<keyword>stage III gastric cancer</keyword>
	<keyword>adenocarcinoma stomach</keyword>
</DOC>